NCT01933529View on ClinicalTrials.gov

ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)

PHASE2UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

December 31, 2015

Conditions
Diabetes Type 2Impaired Glucose ToleranceImpaired Fasting Glucose
Interventions
DRUG

ARA 290

ARA 290 is injected s.c. once daily during the study period

Trial Locations (1)

17176

Dept of Endocrinology and Diabetes, Karolinska University Hospital, Stockholm

Sponsors
All Listed Sponsors
collaborator

Araim Pharmaceuticals, Inc.

INDUSTRY

lead

Claes-Göran Östenson

OTHER

NCT01933529 - ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes) | Biotech Hunter | Biotech Hunter